Pharming Group (PHAR) to Release Earnings on Thursday

Key Points

• Q4 2025 results due before market open on March 12, 2026, with analysts expecting EPS of $0.15 and revenue of $111.759 million and a conference call scheduled for 1:30 PM ET.
• Shares opened at $16.22 (trading up ~5.3%), with a 52-week range of $7.50–$21.34 and a market capitalization of about $1.14 billion; the stock currently has a negative P/E.
• Several institutions recently adjusted positions but institutional ownership remains tiny at 0.03%; Wall Street sentiment is split (two Buy, two Hold) with a consensus rating of Moderate Buy and an average price target of $38.00.

Pharming Group (NASDAQ:PHAR - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Pharming Group to post earnings of $0.15 per share and revenue of $111.7590 million for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Pharming Group Trading Up 5.3%

Shares of PHAR stock opened at $16.22 on Thursday. Pharming Group has a fifty-two week low of $7.50 and a fifty-two week high of $21.34. The company has a 50 day moving average price of $17.46 and a 200 day moving average price of $15.95. The stock has a market capitalization of $1.14 billion, a P/E ratio of -1,620.38 and a beta of 0.04. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16.

Institutional Investors Weigh In On Pharming Group

Several hedge funds and other institutional investors have recently made changes to their positions in PHAR. NewEdge Advisors LLC lifted its position in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock worth $510,000 after buying an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new stake in Pharming Group in the fourth quarter valued at approximately $360,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group in the fourth quarter valued at approximately $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on PHAR. Wall Street Zen raised Pharming Group to a "strong-buy" rating in a research report on Saturday, December 27th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pharming Group in a research note on Monday, December 22nd. Finally, Zacks Research lowered Pharming Group from a "strong-buy" rating to a "hold" rating in a research report on Thursday, January 1st. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Pharming Group presently has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.